Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cellsTessa Knox, Alejandro Villagra|Scientific Reports|2019Cited by 160
Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer ImmunotherapyDebarati Banik, Alejandro Villagra|International Journal of Molecular Sciences|2019Cited by 149
The HDAC6 inhibitor AVS100 (SS208) induces a pro-inflammatory tumor microenvironment and potentiates immunotherapyDamián Kovalovsky, Alejandro Villagra|Science Advances|2024Cited by 23